Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

47 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
ALK-Testing in non-small cell lung cancer (NSCLC): Immunohistochemistry (IHC) and/or fluorescence in-situ Hybridisation (FISH)?: Statement of the Germany Society for Pathology (DGP) and the Working Group Thoracic Oncology (AIO) of the German Cancer Society e.V. (Stellungnahme der Deutschen Gesellschaft für Pathologie und der AG Thorakale Onkologie der Arbeitsgemeinschaft Onkologie/Deutsche Krebsgesellschaft e.V.).
von Laffert M, Schirmacher P, Warth A, Weichert W, Büttner R, Huber RM, Wolf J, Griesinger F, Dietel M, Grohé C. von Laffert M, et al. Lung Cancer. 2017 Jan;103:1-5. doi: 10.1016/j.lungcan.2016.11.008. Epub 2016 Nov 14. Lung Cancer. 2017. PMID: 28024689
Next generation sequencing of lung adenocarcinoma subtypes with intestinal differentiation reveals distinct molecular signatures associated with histomorphology and therapeutic options.
Jurmeister P, Vollbrecht C, Behnke A, Frost N, Arnold A, Treue D, Rückert JC, Neudecker J, Schweizer L, Klauschen F, Horst D, Hummel M, Dietel M, von Laffert M. Jurmeister P, et al. Among authors: von laffert m. Lung Cancer. 2019 Dec;138:43-51. doi: 10.1016/j.lungcan.2019.10.005. Epub 2019 Oct 11. Lung Cancer. 2019. PMID: 31634654
Multicenter immunohistochemical ALK-testing of non-small-cell lung cancer shows high concordance after harmonization of techniques and interpretation criteria.
von Laffert M, Warth A, Penzel R, Schirmacher P, Kerr KM, Elmberger G, Schildhaus HU, Büttner R, Lopez-Rios F, Reu S, Kirchner T, Pauwels P, Specht K, Drecoll E, Höfler H, Aust D, Baretton G, Bubendorf L, Stallmann S, Fisseler-Eckhoff A, Soltermann A, Tischler V, Moch H, Penault-Llorca F, Hager H, Schäper F, Lenze D, Hummel M, Dietel M. von Laffert M, et al. J Thorac Oncol. 2014 Nov;9(11):1685-92. doi: 10.1097/JTO.0000000000000332. J Thorac Oncol. 2014. PMID: 25436802 Free article.
Status quo of ALK testing in lung cancer: results of an EQA scheme based on in-situ hybridization, immunohistochemistry, and RNA/DNA sequencing.
Jurmeister P, Vollbrecht C, Jöhrens K, Aust D, Behnke A, Stenzinger A, Penzel R, Endris V, Schirmacher P, Fisseler-Eckhoff A, Neumann J, Kirchner T, Büttner R, Merkelbach-Bruse S, Kreipe H, Jonigk D, Jochum W, Rodriguez R, Dietel M, Horst D, Hummel M, von Laffert M. Jurmeister P, et al. Among authors: von laffert m. Virchows Arch. 2021 Aug;479(2):247-255. doi: 10.1007/s00428-021-03106-5. Epub 2021 Jun 25. Virchows Arch. 2021. PMID: 34173019 Free PMC article.
Immunohistochemical analysis of Bcl-2, nuclear S100A4, MITF and Ki67 for risk stratification of early-stage melanoma - A combined IHC score for melanoma risk stratification.
Jurmeister P, Bockmayr M, Treese C, Stein U, Lenze D, Jöhrens K, Friedling F, Dietel M, Klauschen F, Marsch W, Fiedler E, von Laffert M. Jurmeister P, et al. Among authors: von laffert m. J Dtsch Dermatol Ges. 2019 Aug;17(8):800-808. doi: 10.1111/ddg.13917. J Dtsch Dermatol Ges. 2019. PMID: 31437373
47 results